Clinical Trial Update: A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CP-601,927 as augmentation to antidepressant therapy in major depressive disorder; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• CP-601,927

Snippet

Sponsor: Pfizer | Conditions: Major Depressive Disorder | Phase 2 | Status: TERMINATED | Results posted: 2013-06-26